Header Logo

Connection

VINCENT TAM to Anti-Bacterial Agents

Back to Details
This is a "connection" page, showing publications VINCENT TAM has written about Anti-Bacterial Agents.
VINCENT TAM
Connection Strength
16.618
Anti-Bacterial Agents
  1. Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A?case report. Pharmacotherapy. 2025 Jan; 45(1):66-69.
    View in: PubMed
    Score: 0.422
  2. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
    View in: PubMed
    Score: 0.410
  3. Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145.
    View in: PubMed
    Score: 0.407
  4. Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193.
    View in: PubMed
    Score: 0.405
  5. Comparison of cefiderocol in-vitro susceptibility testing modalities. J Glob Antimicrob Resist. 2024 06; 37:100-101.
    View in: PubMed
    Score: 0.402
  6. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471.
    View in: PubMed
    Score: 0.349
  7. Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
    View in: PubMed
    Score: 0.325
  8. Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809.
    View in: PubMed
    Score: 0.321
  9. A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies. Bioanalysis. 2020 Apr; 12(7):445-454.
    View in: PubMed
    Score: 0.307
  10. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3).
    View in: PubMed
    Score: 0.303
  11. Toxicity in Patients. Adv Exp Med Biol. 2019; 1145:289-304.
    View in: PubMed
    Score: 0.280
  12. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.
    View in: PubMed
    Score: 0.277
  13. Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294.
    View in: PubMed
    Score: 0.265
  14. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
    View in: PubMed
    Score: 0.261
  15. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634.
    View in: PubMed
    Score: 0.251
  16. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428.
    View in: PubMed
    Score: 0.249
  17. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).
    View in: PubMed
    Score: 0.249
  18. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 04; 61(4).
    View in: PubMed
    Score: 0.247
  19. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.243
  20. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.
    View in: PubMed
    Score: 0.240
  21. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.
    View in: PubMed
    Score: 0.237
  22. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
    View in: PubMed
    Score: 0.214
  23. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.
    View in: PubMed
    Score: 0.213
  24. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
    View in: PubMed
    Score: 0.213
  25. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370.
    View in: PubMed
    Score: 0.210
  26. Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339.
    View in: PubMed
    Score: 0.208
  27. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.
    View in: PubMed
    Score: 0.207
  28. Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44.
    View in: PubMed
    Score: 0.204
  29. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21.
    View in: PubMed
    Score: 0.203
  30. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2.
    View in: PubMed
    Score: 0.202
  31. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6.
    View in: PubMed
    Score: 0.200
  32. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9.
    View in: PubMed
    Score: 0.196
  33. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.
    View in: PubMed
    Score: 0.193
  34. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10.
    View in: PubMed
    Score: 0.185
  35. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.
    View in: PubMed
    Score: 0.178
  36. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
    View in: PubMed
    Score: 0.176
  37. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct; 11(5):453-6.
    View in: PubMed
    Score: 0.168
  38. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1.
    View in: PubMed
    Score: 0.166
  39. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J. 2011 Jun; 30(6):537-9.
    View in: PubMed
    Score: 0.165
  40. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis. 2011 May; 52(10):1278-9; author reply 1279-80.
    View in: PubMed
    Score: 0.164
  41. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1.
    View in: PubMed
    Score: 0.164
  42. Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86.
    View in: PubMed
    Score: 0.163
  43. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov; 54(11):4739-43.
    View in: PubMed
    Score: 0.157
  44. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother. 2010 Oct; 54(10):4262-8.
    View in: PubMed
    Score: 0.156
  45. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15; 67(14):1191-4.
    View in: PubMed
    Score: 0.156
  46. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun; 65(6):1119-25.
    View in: PubMed
    Score: 0.153
  47. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis. 2010 Mar 15; 201(6):889-97.
    View in: PubMed
    Score: 0.152
  48. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4.
    View in: PubMed
    Score: 0.150
  49. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents. 2010 Mar; 35(3):308-10.
    View in: PubMed
    Score: 0.150
  50. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4.
    View in: PubMed
    Score: 0.147
  51. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009 Aug; 64(4):427-33.
    View in: PubMed
    Score: 0.146
  52. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother. 2009 Sep; 64(3):556-62.
    View in: PubMed
    Score: 0.145
  53. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009 Jun; 64(2):166-71.
    View in: PubMed
    Score: 0.142
  54. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn Microbiol Infect Dis. 2009 Jan; 63(1):81-6.
    View in: PubMed
    Score: 0.138
  55. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4.
    View in: PubMed
    Score: 0.138
  56. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93.
    View in: PubMed
    Score: 0.137
  57. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May; 17(5):661-8.
    View in: PubMed
    Score: 0.134
  58. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.132
  59. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007 Dec; 60(6):1302-9.
    View in: PubMed
    Score: 0.128
  60. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27.
    View in: PubMed
    Score: 0.125
  61. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7.
    View in: PubMed
    Score: 0.121
  62. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother. 2006 Nov; 50(11):3950-2.
    View in: PubMed
    Score: 0.119
  63. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Aug; 50(8):2626-31.
    View in: PubMed
    Score: 0.118
  64. Mathematical modelling of resistance emergence. J Antimicrob Chemother. 2005 Nov; 56(5):983; author reply 983-4.
    View in: PubMed
    Score: 0.111
  65. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30.
    View in: PubMed
    Score: 0.111
  66. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005 Jun; 52(2):145-51.
    View in: PubMed
    Score: 0.109
  67. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother. 2005 May; 55(5):699-706.
    View in: PubMed
    Score: 0.108
  68. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
    View in: PubMed
    Score: 0.104
  69. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
    View in: PubMed
    Score: 0.097
  70. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61.
    View in: PubMed
    Score: 0.095
  71. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2).
    View in: PubMed
    Score: 0.093
  72. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
    View in: PubMed
    Score: 0.092
  73. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
    View in: PubMed
    Score: 0.091
  74. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8.
    View in: PubMed
    Score: 0.090
  75. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346.
    View in: PubMed
    Score: 0.085
  76. Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0199621.
    View in: PubMed
    Score: 0.085
  77. New antibiotics for infections caused by resistant organisms. Support Care Cancer. 2001 Jan; 9(1):8-10.
    View in: PubMed
    Score: 0.080
  78. Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
    View in: PubMed
    Score: 0.080
  79. MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387.
    View in: PubMed
    Score: 0.080
  80. Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250.
    View in: PubMed
    Score: 0.079
  81. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy. 2000 Sep; 20(9):1116-9.
    View in: PubMed
    Score: 0.079
  82. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 08 20; 64(9).
    View in: PubMed
    Score: 0.078
  83. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.
    View in: PubMed
    Score: 0.074
  84. Vancomycin peak serum concentration monitoring. J Intraven Nurs. 1999 Nov-Dec; 22(6):336-42.
    View in: PubMed
    Score: 0.074
  85. Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 05; 63(5).
    View in: PubMed
    Score: 0.071
  86. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).
    View in: PubMed
    Score: 0.070
  87. A novel framework to compare the effectiveness of ?-lactamase inhibitors against extended-spectrum ?-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect. 2019 Sep; 25(9):1154.e9-1154.e14.
    View in: PubMed
    Score: 0.070
  88. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39.
    View in: PubMed
    Score: 0.070
  89. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.063
  90. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7).
    View in: PubMed
    Score: 0.063
  91. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017 Jul; 43(7):1021-1032.
    View in: PubMed
    Score: 0.062
  92. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29.
    View in: PubMed
    Score: 0.058
  93. An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 09; 6:75-77.
    View in: PubMed
    Score: 0.058
  94. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016 Feb; 60(2):1029-34.
    View in: PubMed
    Score: 0.057
  95. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81.
    View in: PubMed
    Score: 0.052
  96. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
    View in: PubMed
    Score: 0.052
  97. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan; 58(1):139-41.
    View in: PubMed
    Score: 0.049
  98. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.044
  99. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5.
    View in: PubMed
    Score: 0.043
  100. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5.
    View in: PubMed
    Score: 0.042
  101. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8.
    View in: PubMed
    Score: 0.038
  102. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.035
  103. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singap. 2008 Oct; 37(10):870-83.
    View in: PubMed
    Score: 0.034
  104. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008 Jul; 62(1):168-71.
    View in: PubMed
    Score: 0.033
  105. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21.
    View in: PubMed
    Score: 0.032
  106. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.032
  107. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104.
    View in: PubMed
    Score: 0.031
  108. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.
    View in: PubMed
    Score: 0.028
  109. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 01 10; 68(1):e0100923.
    View in: PubMed
    Score: 0.025
  110. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul; 112(2):275-85.
    View in: PubMed
    Score: 0.024
  111. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
    View in: PubMed
    Score: 0.023
  112. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212.
    View in: PubMed
    Score: 0.023
  113. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119.
    View in: PubMed
    Score: 0.016
  114. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.016
  115. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7.
    View in: PubMed
    Score: 0.012
  116. Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.